Why the study?
Acute ischemic stroke patients with hypertension have worse outcomes, possibly from renin-angiotensin system overactivation, prompting investigation into whether prestroke antihypertensive treatments affect stroke severity and neurological outcomes after successful endovascular therapy.
Do prestroke RAS inhibitors reduce baseline stroke severity and intracranial hemorrhage in hypertensive patients with acute ischemic stroke treated by endovascular therapy?
Do prestroke RAS inhibitors reduce baseline stroke severity and intracranial hemorrhage in hypertensive patients with acute ischemic stroke treated by endovascular therapy?
Prestroke use of RAS inhibitors is associated with less severe acute ischemic stroke and lower rates of intracranial hemorrhage compared to non-RAS inhibitors in patients undergoing endovascular therapy.
No takes yet. Share an insight, caveat, or question.
Prestroke RAS inhibitor use was associated with milder presentation and less ICH after EVT; leaves open whether AHT class affects outcomes in prospective trials.
A 2022 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: